Conditions: Non-Small Cell Lung Cancer
Keywords: brain metastases Sunitinib Phase 2
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 66
Healthy volunteers: no

Brief summary:
This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Sunitinib
Intervention descriptions: intervention 1: Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity

Protocol document: